Point72 Asset Management L.P. Boosts Position in Annexon, Inc. (NASDAQ:ANNX)

Point72 Asset Management L.P. lifted its stake in shares of Annexon, Inc. (NASDAQ:ANNX - Free Report) by 5.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,626,796 shares of the company's stock after acquiring an additional 299,798 shares during the period. Point72 Asset Management L.P. owned 5.28% of Annexon worth $28,865,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in ANNX. E Fund Management Co. Ltd. lifted its holdings in Annexon by 36.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company's stock valued at $79,000 after purchasing an additional 4,086 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Annexon by 6.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 63,402 shares of the company's stock valued at $325,000 after buying an additional 4,092 shares during the last quarter. Comerica Bank lifted its stake in shares of Annexon by 22.7% during the fourth quarter. Comerica Bank now owns 23,183 shares of the company's stock valued at $119,000 after buying an additional 4,283 shares during the period. Wellington Management Group LLP lifted its stake in shares of Annexon by 1.8% during the fourth quarter. Wellington Management Group LLP now owns 268,166 shares of the company's stock valued at $1,376,000 after buying an additional 4,806 shares during the period. Finally, Rhumbline Advisers boosted its position in Annexon by 4.3% during the fourth quarter. Rhumbline Advisers now owns 141,852 shares of the company's stock worth $728,000 after acquiring an additional 5,854 shares during the last quarter.

Analyst Upgrades and Downgrades

ANNX has been the topic of several recent analyst reports. Needham & Company LLC reduced their target price on Annexon from $16.00 to $11.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. HC Wainwright dropped their price objective on shares of Annexon from $20.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th.

Annexon Price Performance

NASDAQ:ANNX traded up $0.05 during trading hours on Thursday, reaching $2.02. 391,902 shares of the company were exchanged, compared to its average volume of 1,780,401. The firm has a market cap of $221.07 million, a price-to-earnings ratio of -1.92 and a beta of 1.24. The stock has a 50 day simple moving average of $1.88 and a 200 day simple moving average of $3.57. Annexon, Inc. has a 52-week low of $1.29 and a 52-week high of $7.85.

Annexon (NASDAQ:ANNX - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.07). On average, analysts predict that Annexon, Inc. will post -0.96 EPS for the current fiscal year.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.